We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life.
Continuing to
Grow & Invest
We are an evergreen fund that has a long-term investment perspective.
Focusing on the
Mid-Atlantic Region
We invest in life-science companies in the Mid-Atlantic region.
Launching Successful
Companies
Our portfolio companies have attracted over $4.4 billion of external capital to support their growth.
Latest News
AllAccelerated BiosciencesAcuity PharmaceuticalsAlleviAlterisAnnovisAtalanAvid RadiopharmaceuticalsBainbridge HealthBioAdvance NewsBobcatBioCeptarisCohero HealthConcarlo TherapeuticsCrossBridgeEliksa TherapeuticsENB TherapeuticsGeneralHalo LabsHanimune TherapeuticsHealthQxHueDxImmunoGenesisImmunomeInfraScanInnervaceIntezyneiView TherapeuticsKaloCyteKayotheraKeritonLadder BioLatusLumenVuMebias DiscoveryMelior DiscoveryMidway PharmaceuticalsNovira TherapeuticsNuPatheOncora MedicalOnspira TherapeuticsOpsidioOssianixPalvella TherapeuticsPhrase HealthPillo HealthPortfolio NewsProtez PharmaceuticalsPSTRelmada TherapeuticsRenovacorRide HealthSenzoStradosThe One Health CompanyTolerance BioTreventis CorporationVenatorx PharmaceuticalsVesteckVittoria BiotherapeuticsWellsheet
Elsevier acquires Wellsheet to close the gap between patient data and clinical evidence at the point of care
Elsevier acquires Wellsheet to close the gap between patient data and clinical evidence at the point of care
lmmunoGenesis Appoints Chief Medical Officer
lmmunoGenesis Appoints Chief Medical Officer
Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors
Ladder Bio Appoints Jay Fine, PhD and John Prufeta to Board of Directors
Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations